Content Types

Posts

  • New day for antibody-drug conjugates – Chemical & Engineering News
  • What makes a good antibody–drug conjugate? – Martin De Cecco, Daniel N. Galbraith & Lisa L. McDermottt
  • Beacon Targeted Therapies announces the launch of Beacon Oncolytic Viruses
  • Cell Therapy 2.0
  • Overcoming Challenges in the Development of Anticancer ADCs
  • Immuno-oncology cell therapies: commercial considerations and strategies for the new decade
  • Beacon Targeted Therapies announces the launch of Beacon Gene Therapy
  • Frontiers in Oncology – Perspective: Designing T-Cell Engagers With Better Therapeutic Windows
  • Hot Topics at CAR-TCR 2020
  • Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials
  • TCR Therapies Summit 2020 Magazine
  • Drug developers take fresh aim at ‘guided-missile’ cancer drugs
  • CAR-TCR Europe Summit 2020 Magazine
  • World ADC London 2020 Magazine
  • Innate Killer Summit 2020 Magazine
  • From Mylotarg to Polivy: Ebbs and flows, successes and woes of ADCs
  • Trends & Forecasts – Tenacious ADCs
  • World ADC San Diego Magazine 2019
  • Beacon Targeted Therapies expands on Adoptive Cell Clinical Trial and Drug Database Solutions
  • Biomarkers for Checkpoint Inhibition and Their Clinical Utility – Timothy James Fabisiak, B.A.
  • Bispecific antibodies: a mechanistic review of the pipeline Aran F. Labrijn, Maarten L. Janmaat, Janice M. Reichert & Paul W. H. I. Parren
  • Beacon Targeted Therapies Launches Beacon Adoptive Cell
  • The Evolving Shape of the ADC Market: The Widening Application of ADCs and Manufacturing Improvements Meeting Demand – Charlie Johnson, CEO of ADC Bio, adcbio.com
  • Antibodies to watch in 2019 – Hélène Kaplon & Janice M. Reichert
  • Infographics

  • Microbiome Movement Drug Development Presentation
  • Checkpoint ASCO Post-Conference Report 2022
  • Cytokine ASCO Post-Conference Report 2022
  • Bispecific ASCO Post-Conference Report 2022
  • DDR ASCO Post-Conference Report 2022
  • ADC ASCO Post-Conference Report 2022
  • Oncolytic Viruses – Vaccinia Virus Analysis
  • Adoptive Cell – Manufacturing Challenges & Considerations for Allogeneic Cell Therapy
  • Adoptive Cell ASGCT Post-Conference Report 2022
  • Gene Therapy ASGCT Post-Conference Report 2022
  • Cancer Vaccine ASCO Pre-Conference Planner 2022
  • TPD Beacon Podcast Ep.1
  • DDR ASCO Pre-Conference Planner 2022
  • Gene Therapy ASGCT Pre-Conference Planner 2022
  • RNA ASGCT Pre-Conference Planner 2022
  • TPD ASCO Pre-Conference Planner 2022
  • Cytokine ASCO Pre-Conference Planner 2022
  • Bispecific ASCO Pre-Conference Planner 2022
  • Checkpoint ASCO Pre-Conference Planner 2022
  • RNA AACR Post-Conference Planner 2022
  • ADC ASCO Pre-Conference Planner 2022
  • Oncolytic Viruses ASCO Pre-Conference Planner 2022
  • Adoptive Cell ASCO Pre-Conference Planner 2022
  • The Thriving Interleukin Therapies Landscape: Clinical and Preclinical Key Developments
  • DDR AACR Infographic 2022
  • The CD73 Cancer Clinical Trial Landscape
  • Adoptive Cell AACR Post-Conference Report 2022
  • Oncolytic Viruses AACR Post-Conference Report 2022
  • Cancer Vaccine AACR Post-Conference Report 2022
  • TPD AACR Post-Conference Report 2022
  • Cytokine AACR Post-Conference Report 2022
  • Bispecific AACR Post-Conference Report 2022
  • ADC AACR Post-Conference Report 2022
  • Checkpoint AACR Post-Conference Report 2022
  • The RNA Landscape and Beyond Presentation
  • Gene Therapy AAV Durability Report
  • RNA AACR Pre-Conference Planner 2022
  • Adoptive Cell AACR Pre-Conference Planner 2022
  • Cancer Vaccine AACR Pre-Conference Planner 2022
  • Checkpoint AACR Pre-Conference Planner 2022
  • Bispecific AACR Pre-Conference Planner 2022
  • Cytokine AACR Pre-Conference Planner 2022
  • ADC AACR Pre-Conference Planner 2022
  • TPD AACR Pre-Conference Planner 2022
  • Oncolytic Viruses AACR Pre-Conference Planner 2022
  • DDR AACR Pre-Conference Planner 2022
  • RNA Infographic 2022
  • Landscape Reviews
  • DDR Interview Dec 2021
  • TPD Infographic 2021
  • RNA Infographic 2021
  • ADC Infographic 2021
  • Cytokine Infographic 2021
  • ADC Infographic 2021
  • Cancer Vaccine Infographic 2021
  • Gene Therapy Infographic 2021
  • DDR Infographic June 2021
  • Oncolytic Viruses Infographic 2021
  • TPD Infographic 2021
  • Bispecific Infographic 2021
  • Adoptive Cell Infographic 2021
  • DDR Infographic 2021
  • Checkpoint Thought Paper 2020
  • Adoptive Cell Infographic 2020
  • Bispecific Infographic 2020
  • Checkpoint Infographic 2020
  • Gene Therapy Infographic 2020
  • ADC Infographic 2020
  • Oncolytic Viruses Infographic 2020
  • Bispecific and Checkpoint Infographic 2020
  • logo